Provides clinically actionable repurposing evidence for managing perioperative depression in PD—relevant for symptom control and perioperative outcomes—but offers limited insight into disease‑modifying mechanisms or core PD biology.

Microbiome modulation is a plausible, translationally relevant avenue for PD (gut–brain interactions, inflammation, metabolism), but the lack of accessible data or mechanistic/clinical detail limits immediate utility for therapeutic discovery.

Highlights a potentially useful non‑pharmacological, translational avenue for symptom management and improved phenotyping of gait disturbances, but offers limited actionable insights for drug discovery or molecular target development.

Improving discrimination of true beta-burst signals could refine electrophysiological biomarkers and DBS tuning with translational relevance, but absence of an abstract and limited mechanistic or therapeutic content reduce its direct value for drug discovery.

Improved interpretable prediction could help identify candidate biomarkers and stratify patients for trials, but with no abstract and little mechanistic or therapeutic content the paper has limited direct value for drug discovery.

May inform biomarker-based differentiation between PD and tremor disorders and improve early diagnosis, but offers limited direct mechanistic or therapeutic insights for Parkinson's drug discovery.

Although it does not address molecular mechanisms or drug targets, the paper has translational clinical value by informing personalized DBS targeting and predictive modeling to reduce cognitive side effects, which can improve patient outcomes and trial design for neuromodulation interventions.

Relevant to symptomatic management and to understanding autonomic involvement in PD (which could inform biomarkers or peripheral alpha‑synuclein pathology), but with limited immediate value for novel therapeutic discovery given the likely clinical/symptom focus and lack of available abstract.

Cerebral perfusion could reveal vascular contributions, imaging biomarkers, or repurposable vascular interventions for PD, but the editorial format and missing abstract limit immediate actionable or translational value.

It flags epidemiological links between diet and PD that could motivate mechanistic work on gut-brain and metabolic pathways, but as a comment it offers limited actionable insights for therapy development.

Improves identification of anxiety for clinical care and trial assessments in PD but provides limited direct mechanistic or therapeutic discovery insights.

Resolving artifact versus biological signal improves confidence in beta-burst–based biomarkers and electrophysiology-driven trial endpoints, but the paper is low on direct therapeutic mechanisms or translational interventions.

Refines genotype–phenotype characterization that can improve early diagnosis and patient stratification for studies, but presents limited immediate therapeutic or mechanistic insights (abstract missing), so its direct value for drug discovery is low.

Provides a scalable, noninvasive method to quantify motor symptoms and generate clinical biomarkers useful for patient stratification and trial endpoints, but offers little insight into disease mechanisms or therapeutic targets.

Could improve early detection and patient stratification for trials, but offers little direct actionable mechanistic or therapeutic insight for Parkinson's disease drug discovery.

Network signatures can point to biomarkers or convergent pathways for therapeutic targeting and repurposing, but without accessible data or methods this manuscript currently has low actionable value for Parkinson's drug discovery.

The work pertains to diagnostic/biomarker development—which can aid patient stratification and trials—but as a correction with no new data it offers minimal direct value for therapeutic discovery or mechanistic insights.

Offers a validated clinical outcome measure useful for assessing symptom burden and tracking intervention effects in trials, but provides minimal mechanistic or therapeutic-discovery insight.

Although the correction itself offers little actionable therapeutic information, refined conceptual frameworks can still help align biomarker-based patient stratification and research priorities that indirectly support future drug discovery efforts.

Improves clinical staging and may aid patient selection for advanced therapies or trials, but provides little mechanistic or translational insight relevant to therapeutic discovery.